WO2006072259A2 - Taurine synthesis, production and utility as a medicine - Google Patents

Taurine synthesis, production and utility as a medicine Download PDF

Info

Publication number
WO2006072259A2
WO2006072259A2 PCT/EG2005/000044 EG2005000044W WO2006072259A2 WO 2006072259 A2 WO2006072259 A2 WO 2006072259A2 EG 2005000044 W EG2005000044 W EG 2005000044W WO 2006072259 A2 WO2006072259 A2 WO 2006072259A2
Authority
WO
WIPO (PCT)
Prior art keywords
effective
concentrations
prevention
combinations
controlling
Prior art date
Application number
PCT/EG2005/000044
Other languages
English (en)
French (fr)
Other versions
WO2006072259A3 (en
Inventor
Magd Ahmed Kotb Abdalla
Original Assignee
Magd Ahmed Kotb Abdalla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AP2007004084A priority Critical patent/AP2007004084A0/xx
Application filed by Magd Ahmed Kotb Abdalla filed Critical Magd Ahmed Kotb Abdalla
Priority to MX2007008196A priority patent/MX2007008196A/es
Priority to EA200701434A priority patent/EA200701434A1/ru
Priority to JP2007549796A priority patent/JP2008526789A/ja
Priority to EP05818935A priority patent/EP1844006A2/en
Priority to CA002593563A priority patent/CA2593563A1/en
Priority to AU2005324199A priority patent/AU2005324199A1/en
Priority to BRPI0519606-0A priority patent/BRPI0519606A2/pt
Publication of WO2006072259A2 publication Critical patent/WO2006072259A2/en
Priority to TNP2007000226A priority patent/TNSN07226A1/fr
Priority to IL184221A priority patent/IL184221A0/en
Priority to NO20074937A priority patent/NO20074937A/no
Publication of WO2006072259A3 publication Critical patent/WO2006072259A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton

Definitions

  • lipids, lipoproteins, cholesterol, and hypercholestrolaemia associated diseases, psychiatric and neurological diseases and in gall stone dissolution the following singly or combined are effective: a. Taurine b. Cysteine and/or acetyl cysteine, c. All water soluble vitamins.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/EG2005/000044 2005-01-05 2005-12-31 Taurine synthesis, production and utility as a medicine WO2006072259A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA002593563A CA2593563A1 (en) 2005-01-05 2005-12-31 Taurine synthesis, production and utility as a medicine
MX2007008196A MX2007008196A (es) 2005-01-05 2005-12-31 Sintesis, produccion y utilidad de taurina como una medicina.
EA200701434A EA200701434A1 (ru) 2005-01-05 2005-12-31 Тауриновый синтез, производство и применение в качестве лекарственного средства
JP2007549796A JP2008526789A (ja) 2005-01-05 2005-12-31 タウリンの合成、生成及び医薬としての利用
EP05818935A EP1844006A2 (en) 2005-01-05 2005-12-31 Taurine synthesis, production and utility as a medicine
AP2007004084A AP2007004084A0 (en) 2005-01-05 2005-12-31 Taurine synthesis production and utility as a medicine
AU2005324199A AU2005324199A1 (en) 2005-01-05 2005-12-31 Taurine synthesis, production and utility as a medicine
BRPI0519606-0A BRPI0519606A2 (pt) 2005-01-05 2005-12-31 sÍntese, produÇço e utilidade da taurina como um remÉdio
TNP2007000226A TNSN07226A1 (en) 2005-01-05 2007-06-14 Taurine synthesis, production and utility as a medicine
IL184221A IL184221A0 (en) 2005-01-05 2007-06-26 Process for the manufacture of taurine
NO20074937A NO20074937A (no) 2005-01-05 2007-09-28 Taurinsyntese, produksjon og anvendelse som legemiddel

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EG2005010013 2005-01-05
EG2005010013 2005-01-05

Publications (2)

Publication Number Publication Date
WO2006072259A2 true WO2006072259A2 (en) 2006-07-13
WO2006072259A3 WO2006072259A3 (en) 2007-10-04

Family

ID=36647837

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EG2005/000044 WO2006072259A2 (en) 2005-01-05 2005-12-31 Taurine synthesis, production and utility as a medicine

Country Status (15)

Country Link
EP (1) EP1844006A2 (ko)
JP (1) JP2008526789A (ko)
KR (1) KR20070091198A (ko)
CN (1) CN101146767A (ko)
AP (1) AP2007004084A0 (ko)
AU (1) AU2005324199A1 (ko)
BR (1) BRPI0519606A2 (ko)
CA (1) CA2593563A1 (ko)
EA (1) EA200701434A1 (ko)
IL (1) IL184221A0 (ko)
MA (1) MA29238B1 (ko)
MX (1) MX2007008196A (ko)
NO (1) NO20074937A (ko)
TN (1) TNSN07226A1 (ko)
WO (1) WO2006072259A2 (ko)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994226B2 (en) 2007-11-30 2011-08-09 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products
CN103382170A (zh) * 2012-10-25 2013-11-06 潜江永安药业股份有限公司 一种牛磺酸的制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106728405A (zh) * 2016-11-15 2017-05-31 陈思文 一种牛磺酸和水溶性茶多酚复方组合物及其制备方法与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4565830A (en) * 1981-12-22 1986-01-21 Azuma Jun Ichi Method of ameliorating the subjective symptoms and objective signs in congestive heart failure
WO2001026642A2 (en) * 1999-10-08 2001-04-19 Joyce Corinne Bechthold Methods and compositions for treating neurobehavioral disorders
CN1340502A (zh) * 2000-06-30 2002-03-20 张永春 牛磺酸合锌的生产工艺
CN1587362A (zh) * 2004-07-20 2005-03-02 刘辉 牛磺酸功能啤酒及其生产工艺

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08208464A (ja) * 1994-12-02 1996-08-13 Taisho Pharmaceut Co Ltd 高脂血症の治療及び予防薬
US6184227B1 (en) * 1995-07-21 2001-02-06 Savvipharm Inc. Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
SE9601395D0 (sv) * 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 1
GB9722361D0 (en) * 1997-10-24 1997-12-17 Pharma Nord Uk Ltd Pharmaceutical formulation for treating liver disorders
NZ527924A (en) * 1999-01-29 2005-01-28 Mars Uk Ltd Antioxidant compositions and methods for companion animals

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4565830A (en) * 1981-12-22 1986-01-21 Azuma Jun Ichi Method of ameliorating the subjective symptoms and objective signs in congestive heart failure
WO2001026642A2 (en) * 1999-10-08 2001-04-19 Joyce Corinne Bechthold Methods and compositions for treating neurobehavioral disorders
CN1340502A (zh) * 2000-06-30 2002-03-20 张永春 牛磺酸合锌的生产工艺
CN1587362A (zh) * 2004-07-20 2005-03-02 刘辉 牛磺酸功能啤酒及其生产工艺

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1844006A2 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994226B2 (en) 2007-11-30 2011-08-09 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products
US8263662B2 (en) 2007-11-30 2012-09-11 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products
US9149448B2 (en) 2007-11-30 2015-10-06 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products
US9511038B2 (en) 2007-11-30 2016-12-06 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products
US10307386B2 (en) 2007-11-30 2019-06-04 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products
CN103382170A (zh) * 2012-10-25 2013-11-06 潜江永安药业股份有限公司 一种牛磺酸的制备方法
CN103382170B (zh) * 2012-10-25 2015-04-08 潜江永安药业股份有限公司 一种牛磺酸的制备方法

Also Published As

Publication number Publication date
MX2007008196A (es) 2008-02-22
TNSN07226A1 (en) 2008-11-21
IL184221A0 (en) 2008-12-29
AP2007004084A0 (en) 2007-08-31
CN101146767A (zh) 2008-03-19
MA29238B1 (fr) 2008-02-01
WO2006072259A3 (en) 2007-10-04
EP1844006A2 (en) 2007-10-17
CA2593563A1 (en) 2006-07-13
KR20070091198A (ko) 2007-09-07
JP2008526789A (ja) 2008-07-24
EA200701434A1 (ru) 2008-10-30
NO20074937A (no) 2007-09-28
AU2005324199A1 (en) 2006-07-13
BRPI0519606A2 (pt) 2009-02-25

Similar Documents

Publication Publication Date Title
TWI634888B (zh) 治療帕金森疾病的新穎高穿透性藥物和醫藥組合物
IE53432B1 (en) A method for preparing ganglioside derivatives and use thereof in pharmaceutical compositions
EP0951909B1 (en) Combination composition comprising a L-carnitine or an alkanoyl-L-carnitine, a glycosaminoglycan and/or constituent thereof
ITRM930399A1 (it) Uso di esteri della l-carnitina o di acil l- carnitine con idrossiacidi per produrre composizioni farmaceutiche per il trattamento di affezioni cutanee.
WO2006072259A2 (en) Taurine synthesis, production and utility as a medicine
JP5671483B2 (ja) 色素沈着予防又は改善剤
CA3202047A1 (en) Fucosyltransferase specific inhibition using fucose mimetics
JP2017505313A (ja) 新規ｃｙｐ−エイコサノイド誘導体
JP7073384B2 (ja) 化合物及び使用方法
US6451761B1 (en) N′N′-dichlorinated omega-amino acids and uses thereof
JP4226324B2 (ja) カルボン酸型脂質
JP2024014933A (ja) 関節の障害を防止又は処置するためのグルコサミン誘導体
WO2011030727A1 (ja) パンテチンリン酸エステルを含む外用剤
US20090203654A1 (en) Cosmetic and pharmaceutical compositions
JP2021508732A (ja) 関節の障害を防止又は処置するためのグルコサミン誘導体
SK13932002A3 (sk) Farmaceutické kompozície, ktoré obsahujú oligosacharidy, oligosacharidy a ich príprava a použitie
EP1234816A1 (de) Scyphostatin-Analoga als SMase-Inhibitoren
US20160228489A1 (en) Pharmaceutical composition for the prevention and the treatment of degenerative skin disorders especially caused by ionizing radiations
KR102621498B1 (ko) 신규 세라마이드, 그의 제조방법 및 그의 용도
WO2006048430A1 (fr) SELS DE N-ACYL-L-ASPARTATE-β-MONO-ESTER ET/OU DE N-ACYL-L-GLUTAMATE-Ϝ-MONO-ESTER, LEUR PROCÉDÉ DE PRÉPARATION ET LEUR UTILISATION DANS DES COMPOSITIONS THÉRAPEUTIQUE OU COSMÉTIQUE
KR20030003952A (ko) 염증성 피부질환의 예방 및 치료용 조성물
US10745349B2 (en) Ceramide dimer, method for the production thereof, and use of same
EP1957444B1 (en) 2,3,4,5-tetrahydroxy-6-sulfooxyhexanoic acid and its metal salts for medical use
TW202337498A (zh) 用於ｒｎａ遞送之可離子化陽離子脂質
JPH03106896A (ja) ３０位置換グリチルリチン誘導体及びそれを膜形成成分とするリポソーム製剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 556081

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 184221

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12007501399

Country of ref document: PH

Ref document number: 2593563

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005324199

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/008196

Country of ref document: MX

Ref document number: 2007549796

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200580046066.3

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020077016443

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2005324199

Country of ref document: AU

Date of ref document: 20051231

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005324199

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005818935

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 6017/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200701434

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2005818935

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0519606

Country of ref document: BR